Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer

Objectives: Inflammation plays an important role in the pathogenesis of ovarian cancer. The prognostic value of systemic inflam-matory markers is gaining importance in cancer patients. The aim of the present study is to evaluate the clinical and prognostic value of several inflammation markers to include neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and C-reactive protein (CRP), examined pre-operatively in epithelial ovarian cancer patients. Design: Retrospective clinical study. Subjects: A total of 97 patients with epithelial ovarian cancer who underwent primary staging surgery or debulking surgery were analyzed retrospectively. The influence of NLR, PLR values on overall survey (OS) was tested with Kaplan-Meier method and clinical-pathological parameters were tested with chi-square test. Proportional influence of clinical-pathological data on overall survival was tested with hazard ratio univariate and multi-variate analyses. Results: Median values of NLR, PLR and CRP were accepted as cut-off value. While elevated NLR (> 2.94) was associated with elevated CA-125 values (p = 0.002), excess amount of ascites (p = 0.023) and presence of residual tumor (p = 0.036); elevated PLR was associated with elevated CA-125 values (p < 0.001), excess amount of ascites (p = 0.001), presence of residual tumor (p = 0.003) and advanced stage (p = 0.013). Elevated CRP values were associated with only elevated CA-125 values (p = 0.013) and excess amount of ascites (p = 0.046). In uni-variate analysis, presence of post-operative residual tumor, > 500 cc ascites, NLR and PLR values were associated with OS; in multi-variate analysis, only stage (p = 0.019) and presence of post-operative residual tumor (p = 0.016) were found to be independent risk factors for OS. Conclusion: Novel prognostic biomarkers are urgently needed for better prediction of survival and definition of novel therapeutic targets.

Systemic inflammatory markers; Prognosis; Ovarian cancer.

[1] Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A.: “Global cancer statistics, 2012”. CA. Cancer J. Clin., 2015, 65, 87- 108.

[2] Cohen C.A., Shea A.A., Heffron C.L., Schmelz E.M., Roberts P.C.: “The parity-associated microenvironmental niche in the omental fat band is refractory to ovarian cancer metastasis”. Cancer Prev. Res., 2013, 6, 1182-1193.

[3] Siegel R., Ma J., Zou Z., Jemal A.: “Cancer statistics”. CA. Cancer J. Clin., 2014, 64, 9-29.

[4] Berek J.S., Crum C., Friedlander M.: “Cancer of the ovary, fallopian tube, and peritoneum”. Int. J. Gynaecol. Obstet., 2012, 119, S118-S129.

[5] Auer K., Bachmayr-Heyda A., Sukhbaatar N., Aust S., Schmetterer K. G., Meier S.M., et al.: “Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer”. Oncotarget, 2016, 7, 61336-61354.

[6] Hainaut P., Plymoth A.: “Targeting the hallmarks of cancer”. Curr. Opin. Oncol., 2013, 25, 50-51.

[7] Hanahan D., Weinberg R.: “Hallmarks of cancer: the next generation”. Cell, 2011, 144, 646-674.

[8] Stone R.L., Nick A.M., McNeish I.A., Balkwill F., Han H.D., Bottsford-Miller J., et al.: “Paraneoplastic thrombocytosis in ovar-ian cancer”. N. Engl. J. Med., 2012, 366, 610-618.

[9] Liu Y., Chen S., Zheng C., Ding M., Zhang L., Wang L., et al.: “The prognostic value of the preoperative creactive protein/albumin ratio in ovarian cancer”. BMC Cancer, 2017, 17, 285.

[10] Reynés G., Vila V., Martín M., Parada A., Fleitas T., Reganon E., et al.: “Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma”. J. Neurooncol., 2011, 102, 35- 41.

[11] Kemik O., Sumer A., Kemik A.S., Hasirci I., Purisa S., Dulger A. C., et al.: “The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with colon cancer”. World J. Surg. Oncol., 2010, 8, 85.

[12] Hefler L.A., Concin N., Hofstetter G., Marth C., Mustea A., Sehouli J., et al.: “Serum C-reactive protein as independent prognostic vari-able in patients with ovarian cancer”. Clin. Cancer Res., 2008, 14, 710- 714.

[13] Hirashima K., Watanabe M., Shigaki H., Imamura Y., Ida S., Iwat-suki M., et al.: “Prognostic significance of the modified glasgow prognostic score in elderly patients with gastric cancer”. J. Gastroenterol., 2014, 49, 1040-1046.

[14] Oh B.S., Jang J.W., Kwon J.H., You C.R., Chung K.W., Kay C.S., et al.: “Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma”. BMC Cancer, 2013, 13, 78.

[15] Wu N., Chen G., Hu H., Pang L., Chen Z.: “Low pretherapeutic serum albumin as a risk factor for poor outcome in esophageal squamous cell carcinomas”. Nutr. Cancer, 2015, 67, 481-485.

[16] Chua W., Charles K.A., Baracos V.E., Clarke S.J.: “Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer”. Br. J. Cancer, 2011, 104, 1288-1295.

[17] Fader A.N., Rose P.G.: “Role of surgery in ovarian carcinoma”. J. Clin. Oncol., 2007, 25, 2873-2883.

[18] Feng Z., Wen H., Bi R., Ju X., Chen X., Yang W., et al.: “Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer”. Plos. One, 2016, 11, e0156101.

[19] Green S.B., Salkind N.J.: “Using SPSS for windows and macintosh (analyzing and understanding data)”. 5th edition. Pearson Prentice Hall: New Jersey, 2008.

[20] Tabachnick B.G., Fidell L.S.: “Using multivariate statistics”. 2nd ed. The USA: Pearson Education, 2013.

[21] Kang S., Kim T., Nam B., Seo S., Kim B., Bae D., et al.: “Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: A meta-analysis”. J. Surg. Oncol., 2010, 101, 13-17.

[22] Lai I., Daniel M.N., Rosen B.P., May T., Massey C., Feigenberg T.: “Correlation of differential ascites volume with primary cytoreductive surgery outcome, lymph node involvement, and disease recurrence in advanced ovarian cancer”. Int. J. Gynecol. Pathol., 2019, 29, 922-928.

[23] Collett D.: “Modelling Survival Data in Medical Research”., 2015.

[24] Zhang W.W., Liu K.J., Hu G.L., Liang W.J.: “Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients”. Tumor Biol., 2015, 36, 8831-8837.

[25] Templeton A.J., McNamara M.G., Šeruga B., Vera-Badillo F.E., Aneja P., Ocaña A., et al.: “Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis”. J. Natl. Cancer Inst., 2014, 106, 124.

[26] Walsh S.R., Cook E.J., Goulder F., Justin T.A., Keeling N.J.: “Neu-trophil‐lymphocyte ratio as a prognostic factor in colorectal cancer”. J. Surg. Oncol., 2005, 91, 181-184.

[27] Goh B.K.P., Chok A., Allen J.C., Quek R., Teo M.C.C., Chow P.K.H., et al.: “Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors”. Surgery, 2016, 159, 1146-1156.

[28] Zhang G.M., Zhu Y., Ma X.C., Qin X.J., Wan F.N., Dai B., et al.: “Pretreatment neutrophil-to-lymphocyte ratio: a predictor of advanced prostate cancer and biochemical recurrence in patients re-ceiving radical prostatectomy”. Medicine, 2015, 94, e1473.

[29] Han S., Liu Y., Li Q., Li Z., Hou H., Wu A.: “Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T- cell infiltration and predicts clinical outcome in patients with glioblastoma”. BMC Cancer, 2015, 15, 617.

[30] Suppan C., Bjelic-Radisic V., La Garde M., Groselj-Strele A., Eberhard K., Samonigg H., et al.: “Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy”. BMC Cancer, 2015, 15, 1027.

[31] Wang Y., Liu P., Xu Y., Zhang W., Tong L., Guo Z., et al.: “Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinumbased chemotherapy and prognosis in serous ovarian can-cer”. Cancer Chemother. Pharmacol., 2015, 75, 255-262.

[32] Que Y., Qiu H., Li Y., Chen Y., Xiao W., Zhou Z., et al.: “Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma”. BMC Cancer, 2015, 15, 648.

[33] Williams K.A., Labidi-Galy S.I., Terry K.L., Vitonis A.F., Welch W. R., Goodman A., et al.: “Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer”. Gynecol. Oncol., 2014, 132, 542-550.

[34] Suzuki K., Aiura K., Ueda M., Kitajima M.: “The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents”. Pancreas, 2004, 29, 132-140.

[35] Alexandrakis M.G., Passam F.H., Moschandrea I.A., Christophoridou A.V., Pappa C.A., Coulocheri S.A., et al.: “Levels of serum cytokines and acute phase proteins in patients with essential and cancerrelated thrombocytosis”. Am. J. Clin. Oncol., 2003, 26, 135-140.

[36] Asher V., Lee J., Innamaa A., Bali A.: “Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer”. Clin. Transl. Oncol., 2011, 13, 499-503.

[37] Allensworth S.K., Langstraat C.L., Martin J.R., Lemens M.A., Mc-Gree M.E., Weaver A.L., et al.: “Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer”. Gynecol. Oncol., 2013, 130, 499-504.

[38] Na N., Yao J., Cheng C., Huang Z., Hong L., Li H., et al.: “Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors”. Oncotarget, 2016, 7, 44039-44046.

[39] Yang H.B., Xing M., Ma L.N., Feng L.X., Yu Z.: “Prognostic significance of neutrophil-lymphocyteratio/plateletlymphocyteratioin lung cancers: a meta-analysis”. Oncotarget, 2016, 7, 76769-76778.

[40] Chen Y., Chen K., Xiao X., Nie Y., Qu S., Gong C., et al.: “Pre-treatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study”. BMC Cancer, 2016, 16, 320.

[41] Zhu Y., Zhou S., Liu Y., Zhai L., Sun X.: “Prognostic value of systemic inflammatory markers in ovarian cancer: a PRISMA-compliant meta-analysis and systematic review”. BMC Cancer, 2018, 18, 443.

[42] Raungkaewmanee S., Tangjitgamol S., Manusirivithaya S., Sri-jaipracharoen S. and Thavaramara T.: “Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer”. J. Gynecol. Oncol., 2012, 23, 265.

[43] Ceran M.U., Tasdemir U., Colak E., Güngör T.: “Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? a survival analysis”. J. Ovarian Res., 2019, 12, 16.

[44] Friedlander, M.L.: “Prognostic factors in ovarian cancer”. In Seminars in oncology, 1998, 25, 305-314.

[45] Peng H., Yang L., He B., Pan Y., Ying H., Sun H.L. et al.: “Combination of preoperative NLR, PLR and CEA could increase the diagnostic efficacy for I-III stage CRC”. J. Clin. Lab. Anal., 2017, 31, e22075.